#### **Overview** Aurobindo Pharma Limited, headquartered in Hyderabad, India, is an **integrated global pharmaceutical company** founded in 1986. The company operates in over **150 countries** and is recognized as one of the **top 10 generic pharmaceutical companies globally by prescription volume**. It develops, manufactures, and commercializes a diversified portfolio of **generic and branded specialty pharmaceuticals**, including **finished dosage forms (FDFs), active pharmaceutical ingredients (APIs), biosimilars, vaccines, peptides, and complex drug delivery systems**. The business is built on a **vertically integrated model**, with over **30 global manufacturing and packaging facilities** and **nine R&D centers**, enabling cost-effective, scalable, and agile operations across key regulated and emerging markets. --- ### **Core Business Segments & Revenue Streams** | Segment | Key Highlights | |--------|----------------| | **Formulations (86% of Revenue, FY25)** | Generated ₹27,388 crore in FY25. U.S. and Europe together contribute **73%** of total formulation sales. Operates in oral solids, liquids, injectables, transdermal, and respiratory dosages. | | **APIs (14% of Revenue, FY25)** | API business generated ₹4,323 crore in FY25, supporting internal needs (52% in-house consumption) and external customers. One of India’s largest API manufacturers with **19,000 metric tons of annual capacity**. | | **Specialty & Branded Products** | Includes Acrotech Biopharma (U.S. branded oncology) and Eugia Pharma (sterile injectables), driving margin expansion and differentiation. | --- ### **Global Geographic Presence & Market Leadership** - **United States** - Market leader by **prescription volume** (1 out of 10 oral solid prescriptions dispensed). - **#1 position in oral solids**, with a **10% market share (IQVIA, Q3 FY24)**. - Revenue from U.S. formulations: **$1.752 billion (₹15,000 crore+) in FY25**, growing at a 5% CAGR. - 690 **ANDAs approved**, with 861 filed cumulatively (estimated addressable market: **$188 billion**, IQVIA). - Plans to expand onshore manufacturing via **Dayton, NJ (OSD)** and **Raleigh, NC (transdermal, respiratory)**. - **Europe** - **€921 million (₹8,356 crore) in revenue (FY25)**, growing at **22% YoY** and **5% CAGR (5 years)**. - Operates in **10 EU/UK markets**, ranked **top 10 in 8 countries**, including Germany, France, and the UK. - Over **73% of European supply is from in-house manufacturing**, improving profitability. - Targets to cross **€1 billion in FY26 revenue**. - **Growth Markets** - Includes Canada, Brazil, South Africa, Indonesia, and select African and Asian nations. - Generated **₹3,180 crore (FY25)**, with an **18% 5-year CAGR**. - Strong commercial footprint in: - **Canada**: 214 approved products, >50 awaiting approval. - **Indonesia**: Entered via **Pfizer/Viatris brand portfolio acquisition** (Dec 2023); first product approved in China. - Expanding via distributor partnerships in **Algeria and Morocco**. - **ARVs (Antiretrovirals)** - Supplies to **~3 million HIV patients** in over **125 countries**, with **Dolutegravir-based regimens** as core. - Major supplier to **Global Fund, PEPFAR, and South Africa**. - ARV formulations revenue: **₹10,367 crore (FY25)**, up **19.4% YoY**. - Launched **first pediatric ALD (generic)**, recommended by WHO. --- ### **Manufacturing & Supply Chain Capabilities** Aurobindo’s global manufacturing footprint includes: - **18 Formulation Facilities** with installed **FDF capacity >60 billion units** annually. - **13 API & Intermediate Plants**, with **19,000 MT API capacity**. - **Over 30 GMP-compliant sites** approved by **USFDA, EMA, UK MHRA, WHO, and Japan PMDA**. **Key Manufacturing Projects (Commercialization Expected FY26):** - **Taizhou, China Plant**: 2-billion-unit oral solid dosage (OSD) facility, **EU GMP certified**, to serve Chinese, U.S., and EU markets. - **Dayton, NJ (USA)**: New OSD facility enhancing U.S. onshore manufacturing. - **Raleigh, NC (USA)**: Expanding from topical to include **transdermal, inhalation, and injectable** products. - **CuraTeQ Biologics (Hyderabad)**: Biologics CMO with **EU GMP and WHO GMP certifications**; two new **2,500-liter bioreactors** becoming operational. **Backward Integration Focus:** - **Pen-G & 6-APA Facility (Kakinada, India)**: Supports cost-efficient, in-house production of beta-lactam antibiotics. - **GLP-1 & Peptide Expansion**: Building dedicated facilities for high-demand diabetes/obesity APIs. - **Oligonucleotide Synthesis**: New modality under development (target: operational by end-2025). --- ### **Research & Development (R&D) Strategy** - **R&D Investment**: **5.1% of revenue (FY25)**, ~₹1,600 crore. - **Global R&D Team**: **1,500+ scientists and analysts** across **9 centers** (5 in India, 4 in U.S.). - **Focus Areas**: - **Complex Generics & 505(b)(2)**: Nasal sprays, inhalers, depot injectables, and device-based delivery. - **Biosimilars**: 14 in pipeline targeting **$50+ billion market**. - **Peptides, Vaccines, and Transdermal Systems**. **Strategic R&D Tools:** - AI-driven predictive modeling, computational chemistry, and process simulation. - Advanced analytical tools (GC-MS/MS, LC-MS/MS, Raman/NIR) for in-vitro testing. --- ### **Key Strategic Initiatives (2024–2026)** #### **1. Biosimilars – Growth Inflection Point by FY26** - **CuraTeQ Biologics** leads biosimilar development with pipeline: - **Oncology**: Bevacizumab (Avastin biosimilar), Trastuzumab (Xeloda). - **Immunology**: Omalizumab (Xolair), Denosumab (Prolia), Tocilizumab. - **Regulatory Progress**: - **Trastuzumab**, **Bevacizumab**, **Filgrastim**, **Pegfilgrastim** approved in UK/EMA. - **First U.S. FDA biosimilar submission** planned in **FY26**. - Three biosimilars under review in Health Canada and MHRA. - **Market Opportunity**: $120–180 million U.S./Europe revenue by **2028** for Xolair biosimilar alone. #### **2. Complex Generics & Specialty Products** - **Respiratory Portfolio**: - 860+ ANDAs filed in U.S., including **12 nasal sprays** and multiple **MDIs/DPIs**. - Received **FDA approval for Mometasone Furoate Nasal Spray**. - Partnered with a **global pharma major** to co-develop **complex respiratory products**; **$90 million commitment**. - **Injectables & Depot Injections**: - Developing **nano-suspension depot penicillin**, **long-acting injectables**, and **pen/pen injectors**. - 178 ANDAs filed (143 approved) in U.S. for injectables. - **Transdermal & Topicals**: - 69 products in topical portfolio; developing **10 transdermal patches**. - First **transdermal ANDA** filed in FY25. #### **3. Digital & Commercial Enhancements** - Launch of a **digital sales force platform** for real-time performance monitoring. - Use of **IRP (UK)**, **GMP certifications**, and **tender agility** to maintain presence despite regulatory hurdles. - Strengthened **Europe distributor network** via partnership with **Phoenix** (France, UK, Italy, etc.). #### **4. Strategic Acquisitions & Investments** - **Acquisition of Lannett Company LLC (Jul 2025)**: - $250 million deal for U.S.-based complex generics manufacturer. - Adds **3.6 billion-dose OSD capacity**, **CDMO opportunity**, and **500+ employees**. - Strengthens position in **controlled substances and ADHD therapeutics**. - **Acquisition of 17 Viatris/Pfizer Brands in Indonesia (Dec 2023)**: Establishes foothold in Asia’s 4th-largest population. --- ### **Therapeutic Focus Areas** | Area | Key Pipeline/Products | Strategic Goals | |------|------------------------|-----------------| | **Oncology** | Acrotech (7 branded injectables), Eugia (178 ANDAs), multiple biosimilars | Expand in U.S., EU, and Growth Markets | | **Immunology** | 5+ biosimilars (Omalizumab, Denosumab, Ustekinumab) | $4–$5 billion market opportunity | | **Cardiovascular, CNS, Diabetes, Urology** | Complex generic portfolio | Address chronic disease demand | | **Vaccines** | PCV15 via Tergene JV (Phase 3 complete), UB612 (COVID-19, in partnership with Vaxxinity) | Public health solutions in LMICs | | **Peptides** | 14+ GLP-1 and complex peptides in development | Capture diabetes/obesity growth | --- ### **Environmental, Social & Governance (ESG)** - **Renewable Energy**: **37 MW** of installed solar capacity. - **Workforce**: **40,000+ employees** globally. - **Community Engagement**: Active in HIV access programs in Africa, Asia, and Latin America. - **Sustainability in API**: Green enzymatic processes, nitroso/genotoxic impurity controls.